Streetbeat News

Earnings

ITCI

Intra-Cellular Therapies (ITCI) has raised its 2024 net product sales guidance for CAPLYTA to $665M-$685M, up from the previous $650M-$680M. The company also narrowed its SG&A and R&D expense guidance ranges for the year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:43 am

ROCK

Gibraltar Industries has reaffirmed its FY2024 adjusted EPS guidance at $4.11-$4.25, aligning with previous guidance but slightly below the $4.15 analyst estimate. The company also reaffirmed its FY2024 sales guidance at $1.31B-$1.33B, matching previous guidance and slightly below the $1.32B estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:42 am

ABBV

AbbVie has increased its adjusted EPS guidance for 2024 to a range of $10.90-$10.94, up from the previous range of $10.67-$10.87. This new guidance is above the consensus estimate of $10.85.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:41 am

GSK

GSK shares declined following the release of mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:41 am

ABBV

AbbVie reported Q3 2024 earnings per share of $3.00, surpassing the analyst estimate of $2.92. The company's sales reached $14.46 billion, exceeding the expected $14.28 billion and marking a 3.83% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:39 am

ROCK

Gibraltar Industries reported Q3 2024 earnings per share of $1.27, surpassing the analyst estimate of $1.25. The company's sales were $361.196 million, slightly above the expected $360.433 million, but down 7.56% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:38 am

VMC

Vulcan Materials has revised its FY24 adjusted EBITDA expectations to approximately $2 billion, down from the previous range of $2 billion to $2.15 billion, due to a decline in shipments and ongoing weather events in the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:38 am

CLH

Clean Harbors has revised its FY24 Adjusted EBITDA outlook to a range of $1.10B - $1.12B, down from the previous range of $1.125B - $1.165B. The anticipated GAAP net income is now expected to be between $375 million and $395 million, compared to the prior view of $391 million to $426 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:37 am

ITCI

Intra-Cellular Therapies reported a Q3 2024 GAAP EPS of $(0.25), missing the $(0.20) estimate, but sales of $175.375M beat the $172.352M estimate, marking a 39% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:36 am

FTV

Fortive shares are trading higher after the company reported a Q3 EPS beat and provided positive EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:34 am